Raptor Pharmaceutica
Raptor Pharmaceutical to Hold First Quarter 2014 Financial Results Webcast and Conference Call
30 avr. 2014 16h05 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release first quarter 2014 financial results after market close on Thursday,...
Raptor Pharmaceutica
Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Corporate Update
13 mars 2014 16h05 HE | Raptor Pharmaceutical Inc
2014 guidance of $55-$65 million of net sales for PROCYSBI® Company to host conference call and webcast today at 4:30 p.m. EDT NOVATO, Calif., March 13, 2014 (GLOBE NEWSWIRE) -- Raptor...
Raptor Pharmaceutica
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2013 Financial Results Webcast and Conference Call
10 mars 2014 07h30 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release fourth quarter and full year 2013 financial results after market close...
Raptor Pharmaceutica
Raptor Pharmaceutical to Present at Two Upcoming Investor Conferences
24 févr. 2014 07h30 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at two upcoming investor conferences. JMP...
Raptor Announces Ful
Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children
13 janv. 2014 07h00 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103...
Raptor Submits IND f
Raptor Submits IND for RP103 for Leigh Syndrome and Other Mitochondrial Disorders
10 déc. 2013 07h30 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and...
Raptor Pharmaceutica
Raptor Pharmaceutical Corp. Provides PROCYSBI(R) Launch Update and Third Quarter 2013 Financial Results
07 nov. 2013 16h05 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today provided financial results for its third quarter and nine months ended September 30, 2013. PROCYSBI...
Raptor Pharmaceutica
Raptor Pharmaceuticals and DaVita Clinical Research Launch Screening Program to Identify Patients With Late Onset Nephropathic Cystinosis
23 oct. 2013 07h30 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) and DaVita Clinical Research® (DCR®) (NYSE:DVA) today announced a collaboration to screen blood...
Raptor Pharmaceutica
Raptor Pharmaceutical to Hold Third Quarter 2013 Financial Results Webcast and Conference Call
21 oct. 2013 07h30 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release third quarter 2013 financial results after market close on Thursday,...
Raptor Pharmaceutica
Raptor Pharmaceutical to Present at Leerink Swann Rare Disease Roundtable
26 sept. 2013 07h30 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced management will present at the Leerink Swann Rare Disease Roundtable in New York on October...